Circa lists on Euronext Growth Oslo

This page is available in multiple languages

Select Language

Oslo, 2 March 2021 – The Australian biotechnology Circa has today been admitted to trading on Euronext Growth (ticker code: CIRCA).

Circa uses renewable biomass waste to produce biochemicals, and has spent 15 years and five pilots to develop and patent a scalable production process.

Recently, the company raised NOK 500 million through issuing new shares. In addition, there was an over-allotment (greenshoe option) bringing total proceeds raised in the offering to NOK 575 million. The share offering attracted strong support and interest from Norwegian and international investors and was more than 15 times oversubscribed, reported Circa.

“We are both humbled, proud and excited by the reception we have received from investors in both Norway and abroad. Although Australia is far away geographically, we feel very close to the Norwegian financial and industrial community through our strong partnership with Norske Skog. We look forward to further develop our relationship with those communities in the years to come,” says Tony Duncan, CEO and co-founder of Circa Group.

The shares in the new issue were sold at NOK 16.75 corresponding to a market capitalisation of NOK 2.0 billion. Norske Skog ASA invested NOK 50 million in the private placement and holds 26.5 percent of the outstanding shares after the placement.

“Since we first started working with Tony and the Circa team and built the FC 5 pilot plant at the Boyer mill, we have been certain that the Circa technology will be a key enabler for the transition to a more sustainable future within the chemicals industry. We are proud to welcome new shareholders to Circa Group and look forward to working with the development of the Circa business for the benefit of all shareholders of this unique company,” says Lars Sperre, Chairman of Circa Group.

Circa admitted to trading on Euronext Growth Oslo

About Circa

Circa is a biotechnology company that has spent 15 years and five pilots to develop and patent the first scalable LGO production process. LGO is a platform biomolecule used in production of pharmaceuticals, agrochemicals, batteries, graphene, polymers and more. Cyrene is Circa’s first commercial scale biochemical produced from LGO, replacing toxic and fossil-based solvents like NMP and DMF. Circa has received the EU Flagship Grant to support construction of a 1,000 tonnes plant in France.

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.